View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 7, 2022

Pregene and CellPoint to develop cell therapy for haematological indications

CellPoint will make an upfront payment of more than $22m to Pregene under the deal.

Shenzhen Pregene Biopharma and CellPoint have signed an exclusive licence agreement to develop and commercialise the former’s cell therapy, PRG-1801, to treat haematological indications in the US and Europe.

PRG-1801 is a single domain antibody-based anti-BCMA chimeric antigen receptor T cell (CAR-T) programme. 

It uses a humanised single-domain antibody as the antigen-binding domain and lentivirus as a vector. 

As per the deal, Pregene is eligible for an upfront payment of more than $22m (€20m) and near-term consideration from CellPoint.

Pregene is also entitled to receive further payment on meeting development, commercial milestones as well as royalties. 

CellPoint will handle the cell therapy’s development and marketing in the US and Europe. 

Pregene will also offer translational and lentivirus production services, which will be compensated by Cellpoint under the collaboration.

Shenzhen Pregene Biopharma chief technology officer and co-founder Jishuai Zhang said: “The potential of our single domain antibody fully human BCMA CAR-T to treat patients with relapsed/refractory multiple myeloma has been validated in clinical trials of our BCMA autologous CAR-T product candidate. 

“We expect the POC modality to enable faster treatment for broader patients using our differentiated CAR-T therapy, and we look forward to working with the team at CellPoint as they seek to develop and commercialise PRG-1801.”

Being developed to treat relapsed/refractory multiple myeloma, PRG-1801 showed robust signs of efficacy and safety profile in an initial investigator-initiated trial as well as Phase I/II trials.

Apart from multiple myeloma, the company is analysing PRG-1801 for autoimmune diseases. 

In May last year, Pregene entered a license agreement under which Dr. Reddy’s Laboratories attained the exclusive rights for PRG-1801 in India.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU